I
ncreasing evidence suggests that magnesium deficiency may be a key factor in leading to enhanced cardiovascular disease, including hypertension and atherosclerosis. '-8 Studies in isolated vessels indicate that a reduction of magnesium can markedly enhance the response to angiotensin II (Ang II) and norepinephrine. 1 In contrast, increasing the magnesium concentration markedly reduces in vitro pressor responses. 1 Recent studies also indicate that intracellular free magnesium deficiency induced by diet or in diabetes is associated with an increase in platelet aggregation that can be reversed by providing magnesium supplementation. 9 Furthermore, we have shown that dietaryinduced magnesium deficiency in normal humans can augment Ang II-induced increases in blood pressure. 10 Magnesium may reduce blood pressure in part by increasing the production of the vasodilator prostaglandin I 2 (prostacyclin). 1112 However, the effects of magnesium on the production of the vasoconstrictive and proaggregatory prostaglandin thromboxane A 2 (TXA 2 ) are not known.
Several reports have now indicated the presence of low intracellular free magnesium concentrations in subjects with essential hypertension or type II diabetes 9, i3.M i nsu iin resistance has been suggested to be a factor associated with hypertension, atherosclerotic cardiovascular disease, or both. 15 " 19 Some limited evidence also suggests that magnesium may play a role in insulinmediated glucose uptake. 20 ' 21 Therefore, intracellular free magnesium deficiency may be an important link between insulin resistance, hypertension, and accelerated cardiovascular disease. In this report, we evaluated the effect of magnesium supplementation and intracellular magnesium deficiency on TXA 2 production and Ang II-induced aldosterone responses. In addition, insulin sensitivity using a modified intravenous glucose tolerance test (IVGTT) with minimal model analysis was determined before and after magnesium deficiency was induced.
Methods

Protocols
We studied 16 normal subjects that were within 120% of ideal body weight (11 men, 5 women) under approved informed consent at the Clinical Research Center of USC/LA County Medical Center. On one day, the subjects received a 3-hour constant infusion of intravenous MgSO 4 (82.28 mmol Mg/hr) with an IMED pump (IMED Co., San Diego, Calif.) to evaluate the effect of a magnesium load on TXA 2 synthesis and Ang IIinduced aldosterone responses. On another day, the same subjects received an infusion of dextrose in water as a control.
Twelve normal subjects also went on a constant liquid low-magnesium diet (<0.5 mmol/day) for 4 weeks. For the first week of the study, the diet was supplemented with magnesium (400 mg MgCl 2 per day, 164 mmol Slo-Mag, Searle Co., Chicago) in order to study insulin responses in subjects on the identical diet containing magnesium. The diet composition was individualized for each subject as previously described. 22 Calorie needs were determined by providing 147 kJ/kg body wt so that no change in weight would occur. In addition to the liquid diet, oral nutrient supplements were given daily to maintain normal body calcium, potassium, and phosphorus balance. All studies were done with subjects at rest, and activity level was similar between all protocols. The total dairy magnesium content of the diet determined by atomic absorption spectrophotometry was 12 mg. Measurement of erythrocyte magnesium and serum magnesium concentrations were performed two times per week. Compliance with the diet was assessed by measurement of urinary magnesium concentration. After 1 week on the liquid diet replete with magnesium, 3-hour urine was collected and frozen at -20°C for later thromboxane B 2 (TXB2) assay. In addition, an Ang II infusion (7.170 pmol/kg per minute) for 3 hours was performed, and samples were obtained for aldosterone assay. On another day, an IVGTT with minimal model analysis was performed to assess insulin sensitivity. After this, the subjects remained on the same diet without magnesium supplementation for 3 additional weeks. At the conclusion of the 3 weeks on the magnesium-deficient diet, the urine collection, Ang II infusion, and IVGTT with minimal model analysis were repeated.
Methods
Serum and urinary magnesium, potassium, and sodium were measured by standard techniques. Plasma aldosterone concentrations were determined by radioimmunoassay. 23 Plasma renin activity was measured by a previously published method. 24 Urinary TXB2, the stable metabolite of TXA 2 , was measured by a validated radioimmunoassay after extraction on Bond Elute minicolumns and purification by reversed-phase high performance liquid chromatography as previously described.
-26
Free intraceltular magnesium concentration. Free intracellular red blood cell magnesium concentration was determined with nuclear magnetic resonance 922 by a method modified from Resnick et al. 13 Free Mg 2 * concentration can be determined with the dissociation constant according to the published formula.
-22
Intravenous glucose tolerance test with minimal model analysis. In the morning of the study, subjects were placed at bed rest, and bilateral antecubital venous catheters were inserted. At least 45 minutes later, dextrose (16.65 mmol/kg body wt as a 50% solution in water) was injected through one venous catheter, followed in 20 minutes by an injection of tolbutamide (3 mg/kg body wt; Orinase Diagnostic, Upjohn Co., Kalamazoo, Mich.). Blood samples were obtained from the contralateral venous catheter at -15, -10, -5,2,3,4,5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 27, 30, 40, 50, 60, 70, 80, 90 , 100, 120, 140, 160, and 180 minutes relative to the glucose injection, and plasma was separated within 10 minutes and placed at -20°C for subsequent measurement of glucose and insulin concentrations.
Glucose and insulin data from frequently sampled IVGTT were analyzed by the minimal model technique of Bergman et al. 27 - 28 The program generates a measure of insulin sensitivity (S]) that relates the increase in fractional glucose disappearance resultant from an acute rise in circulating insulin during the modified IVGTT to the magnitude of the acute insulin response (units: per minute per microunits per milliliter). Si from the minimal model has been shown to be very closely correlated to insulin sensitivity measured by the glucose clamp technique in people with intact pancreatic B cell function. 29 Other data were analyzed with the CUNFO computer system. Values before and after magnesium supplementation or depletion were compared with the Student's / test or Wilcoxon signed rank test for parametric or nonparametric analysis as appropriate. In studies involving multiple measurements over time, analysis of variance was used. Results are presented as mean±SEM.
Results
Magnesium Infusion Studies
The magnesium infusion increased serum magnesium concentration (0.823±0.08 to 1.72±0.08 mmol/L, /7<0.01) but did change serum sodium, potassium, creatinine, or glucose (data not shown). Urinary TXB 2 concentration was significantly reduced by the magnesium infusion (920±83 pmol/mmol creatinine after magnesium infusion versus l,238±50 pmol control, p<0.02).
The Ang II infusion in the normomagnesemic subjects produced a rise in aldosterone at 60, 120, and 180 minutes during the infusion (Figure 1 ). However, with the addition of magnesium, Ang II produced significantly less of a rise in aldosterone synthesis at both 120 and 180 minutes of infusion ( Figure 1 ).
Isolated Magnesium Deficiency
The low magnesium diet reduced serum magnesium (0.78±0.08 to 0.53±0.08 mmol/L,/><0.01) and intracellular free red blood cell magnesium (186±10 to 127±9 mM,/?<0.01). However, the low magnesium diet did not result in changes in serum sodium (141 ±0.6 versus 142±0.8 mmol/L), potassium (4.1 ±0.09 versus 4.2±0.06 mmol/L), or calcium (2.39±0.02 versus 2.34±0.02 mmol/L). Similarly, plasma renin activity did not show any differences after magnesium deficiency (0.98±0.19 magnesium-replete versus 1.2±0.25 ng/L per second magnesium-deplete). Urinary sodium and potassium were not changed by the diet (data not shown).
The low magnesium diet markedly increased the concentration of TXB2 in urine, as shown in Figure 2 (272±30 magnesium-replete versus 376±90 ng/g creatinine magnesium-deplete or 1,137±125 versus 1,572±376 pmol/mmol creatinine, respectively, p<0.02). The changes in TXB 2 were not due to changes in urinary creatinine clearance or urinary volume (data not shown).
Basal plasma aldosterone concentration was higher in the magnesium-deplete subjects (Figure 3 ). In addition, the Ang II infusion produced a much greater rise in aldosterone concentration in the magnesium-deplete compared with magnesium-replete subjects (37±5 versus 18±2 ng/dL or l,026±139 versus 499±55 pmol/L, p<0.02) (Figure 3) .
Neither fasting serum glucose nor insulin concentration changed after magnesium deficiency (glucose, 5.27±0.27 versus 5.05±0.17 mmol/L; insulin, 58.8+12 versus 64.6±11 pmol/L). However, S r as determined by the IVGTT-minimal model analysis was reduced modestly but significantly in all subjects after induction of isolated magnesium deficiency (Figure 4 ). The S, fell from 3.69±0.6 to 2.75±0.5 after induction of magnesium deficiency in these normal subjects.
Discussion
Evidence indicates that magnesium plays an important role in the regulation of vascular tone and development of atherosclerosis.
1 " 10 Cytosolic magnesium can modulate calcium channel activity and reduce intracellular free calcium concentrations in vascular smooth muscle and platelets. 25 -30 - 33 Furthermore, previous studies in rats and in humans suggest that magnesium can reduce the pressor effects of Ang II. 10 ' 33 In addition, magnesium administration in endothelial cells or in humans stimulates the production of the vasodilator prostaglandin I 2 .
1U2 Consistent with these actions, magnesium has also been shown to modulate platelet aggregation in normal and in diabetic individuals. 9 Indeed, experimental studies have indicated that magnesium administration can reduce the progression of atherosclerosis in animal models and reduce the overall mortality from an acute myocardial infarction by 54%. 3 * In the present report, the potential link between extracellular and intracellular magnesium deficiency, factors associated with elevated blood pressure, and insulin resistance was evaluated. In the first set of studies, a pharmacological infusion of magnesium was administered to test the effects of magnesium on the concentration of the potent vasoconstrictive and platelet proaggregation compound TXA 2 . The results indicate that magnesium can acutely reduce urinary TXA 2 concentration in humans, consistent with other studies in platelets suggesting that magnesium can directly reduce platelet TXA 2 synthesis. 25 Magnesium is not acting as a global inhibitor of prostaglandin synthesis, because our previous study using an identical protocol indicated that magnesium can stimulate urinary prostaglandin I 2 concentrations in humans. 11 Magnesium also reduced the steroidogenic actions of Ang II in humans. In previous reports, it has also been shown that magnesium can reduce Ang II-induced pressor responses. 10 ' 33 A reduced intracellular free magnesium concentration in erythrocytes has been reported in patients with essential hypertension and non-insulin-dependent diabetes.
9 ' 13 ' 14 Because less than 1% of magnesium is found extracellularly and the free intracellular fraction is the portion regulating enzyme pathways, intracellular free magnesium determinations using nuclear magnetic resonance or the new fluorescent magnesium probes will be needed to clarify the role of magnesium in human vascular disease. The present report uses a dietary approach to induce both extracellular and intracellular free magnesium deficiency in normal subjects. We previously reported that this technique induces magnesium deficiency within 3 weeks. 22 Furthermore, we showed that Ang II-induced pressor responses and platelet reactivity were increased after induction of magnesium deficiency. 910 In this article, we now reveal that magnesium deficiency can also increase the concentration of TXA 2 as reflected by the levels of the stable metabolite TXB 2 in urine. In addition, basal aldosterone levels and the steroidogenic effects of Ang II are increased after induction of magnesium defi- To determine whether magnesium deficiency could provide a link between insulin resistance and altered vascular parameters associated with hypertension, we used the IVGTT-minimal model technique. Evidence suggests that the minimal model method is a viable alternative to the glucose clamp for analyzing insulin sensitivity in subjects with intact beta cell function. 24 The results in the present study indicate for the first time that dietary-induced isolated magnesium deficiency in lean subjects leads to a significant reduction in insulin sensitivity. Because the diet itself could lead to changes of insulin action independent of magnesium effects, we performed the baseline studies using the identical diet with sufficient magnesium supplementation to maintain normal magnesium status.
S1UM DEFICIENCY
INSULIN RESISTANCE ALTERED SYNTHESIS OF E1C0SAH01DS ENHANCED
Other limited evidence suggests that magnesium deficiency may alter insulin action. In one recent report, sheep fed a low-magnesium diet showed a reduced mean glucose disposal rate at all insulin concentrations during a euglycemic clamp. 37 Furthermore, studies in isolated muscle have shown that omission of magnesium can reduce insulin-mediated glucose transport. 38 The mechanisms of how magnesium deficiency can alter insulin action are not clear. However, it appears that magnesium does not change in insulin binding. Other evidence shows magnesium deficiency can lead to changes in cellular calcium levels.
-
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- 32 Increased intracellular calcium has been reported to lead to insulin resistance 39 ' 40 ; therefore, magnesium deficiency may lead to a reduction in insulin action by increasing free calcium levels. However, further studies will be required to test this interesting hypothesis. It is also possible that magnesium deficiency can directly alter enzyme activity involved in glucose metabolism. 41 Based on the results of the present report and others, we propose the following hypothesis for how magnesium deficiency, insulin resistance, and hypertension are linked ( Figure 5 ). Magnesium deficiency can lead to both an increase in Ang II-induced rise in blood pressure and aldosterone concentration. In addition, magnesium deficiency would lead to a change in prostaglandin synthesis reflected by a reduction in prostaglandin I 2 and an increase in vasoconstrictive prostaglandins such as TXA 2 and the lipoxygenase product 12-hydroxyeicosatetraenoic acid. These changes would lead to an increase in platelet aggregation and release in growth factors as well as to direct vasoconstrictive actions. Finally, magnesium deficiency through a yet undefined mechanism could produce insulin resistance. Further study evaluating the effects of magnesium supplementation would be required to confirm this hypothesis and whether insulin resistance in the presence of magnesium deficiency can lead directly to hypertension.
